Harvard Bioscience, Inc. HBIO
8.67 USD +0.07 (+0.81%)
At closeNov 3, 2026, 4:00 PM EST
8.67 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
8.60 Day range 8.81
4.00 52-week range 9.10
- YTD
- +29.40%
- 1 year
- +52.11%
Analyst view
Price target (mean) 6.25 -27.9% downside
Now 8.67
- Target (low)
- 5.50
- Target (mean)
- 6.25
- Target (high)
- 7.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 2
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.05 | 0.04 – 0.06 | 0.04 | +25.0% | 24.15M | -14.2% | 2 |
| Next quarter | 0.015 | -0.01 – 0.04 | 0.02 | -25.0% | 22.95M | -6.4% | 2 |
| Current year | 0.045 | 0.00 – 0.09 | 0.14 | -67.9% | 93.75M | -16.5% | 2 |
| Next year | 0.125 | 0.07 – 0.18 | 0.045 | +177.8% | 97.80M | +4.3% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 22, 2023 | Benchmark | Reiterated | Speculative Buy | Speculative Buy |
| Apr 26, 2023 | Benchmark | Maintained | — | Buy |
| Apr 26, 2023 | Keybanc | Maintained | — | Overweight |
| Mar 10, 2023 | Benchmark | Reiterated | — | Buy |
| Nov 9, 2022 | Keybanc | Maintained | — | Overweight |
| Aug 5, 2022 | Keybanc | Maintained | — | Overweight |
| Nov 10, 2020 | Keybanc | Initiated | — | Overweight |
| Feb 27, 2020 | Benchmark | Maintained | — | Speculative Buy |
| Nov 17, 2016 | Singular Research | Initiated | — | Buy |
| Jul 28, 2015 | Benchmark | Initiated | — | Buy |
| Nov 26, 2013 | Sidoti & Co. | Upgrade | Neutral | Buy |